Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 4/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180434 | 0.89 | CHEK1 (0.50) | EGFRCHEK1AURKATNK2MAP2K1 | |
| SCHEMBL2182306 | 0.89 | EGFR (0.40) | EGFRCHEK1AURKA | |
| SCHEMBL12409604 | 0.89 | EGFR (0.40) | EGFRCHEK1AURKA | |
| SCHEMBL3072266 | 0.87 | CHEK1 (0.39) | EGFRCHEK1AURKARXRARXRB | |
| SCHEMBL3072332 | 0.86 | AURKA (0.39) | EGFRCHEK1AURKARXRARXRB | |
| SCHEMBL2182310 | 0.85 | EGFR (0.41) | EGFRCHEK1AURKATNK2MAP2K1 | |
| SCHEMBL6750708 | 0.83 | KDM4E (0.54) | EGFRCHEK1AURKATNK2 | |
| SCHEMBL6750702 | 0.83 | KDM4E (0.54) | EGFRCHEK1AURKATNK2 | |
| SCHEMBL4531353 | 0.83 | AURKA (0.45) | EGFRCHEK1AURKATNK2 | |
| SCHEMBL4530234 | 0.83 | KDM4E (0.54) | EGFRCHEK1AURKATNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMS | EGFR 3016/4885CHEK1 915/4885AURKA 2963/4885 |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | EGFR 4267/4885CHEK1 800/4885AURKA 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.